{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:28:07Z","timestamp":1773815287219,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS), is a rare and highly aggressive B-cell lymphoma with overlapping morphologic and immunophenotypic features that complicate distinction from other aggressive B-cell lymphomas. Disseminated extranodal involvement, absence of lymphadenopathy, and lack of standardized treatment guidelines pose significant diagnostic and therapeutic challenges in HGBL-NOS. We report a 27-year-old female who presented with a six-month history of progressive left-sided chest pain, dyspnea, hemoptysis, and dry cough without constitutional B symptoms. Laboratory evaluation revealed anemia and markedly elevated lactate dehydrogenase (LDH) levels. Imaging revealed a large, heterogeneous mass in the anterior left lung with disseminated extranodal involvement of 11 organs, including the lungs, heart, brain, kidneys, adrenal glands, uterus, spleen, pancreas, bone, skeletal muscle, and thyroid, in the absence of lymphadenopathy. Endobronchial ultrasound-guided transbronchial (EBUS) biopsy confirmed infiltration by atypical large B-cell lymphoid cells. Immunohistochemistry revealed diffuse positivity for CD20, CD10, and BCL6, with C-MYC expression in 40% of tumor cells and a Ki-67 proliferation index of 90%. The patient received R-CEOP for cytoreduction, followed by four cycles of intensive R-CODOX-M\/IVAC chemotherapy, with dose adjustment based on hepatic and cardiac tolerance. Post-treatment positron emission tomography\/computed tomography (PET\/CT) confirmed complete metabolic remission. This case highlights an exceptionally rare and aggressive presentation of HGBL-NOS with extensive extranodal dissemination involving 11 organs in the absence of lymphadenopathy, underscoring the importance of early integrated diagnostic approaches and prompt initiation of intensive chemotherapy to achieve favorable outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2026.1781511","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:31Z","timestamp":1773812131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HGBL-NOS presenting as widespread extranodal disease without lymphadenopathy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohammad Fuad","family":"Sayes","sequence":"first","affiliation":[{"name":"Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sabbah","sequence":"additional","affiliation":[{"name":"Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Karama","sequence":"additional","affiliation":[{"name":"Al-Quds University","place":["Jerusalem, Palestine"]},{"name":"Department of Hematology & Oncology, Istishari Arab Hospital","place":["Ramallah, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Allan","sequence":"additional","affiliation":[{"name":"Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basel","family":"Bader","sequence":"additional","affiliation":[{"name":"Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohannad","family":"Abulihya","sequence":"additional","affiliation":[{"name":"Department of Pathology, Istishari Arab Hospital","place":["Ramallah, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020008374","article-title":"Defining and treating high-grade B-cell lymphoma, NOS","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620\u20132","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1182\/BLOODADVANCES.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2141.2011.08947.X","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u201cunclassifiable\u201d highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDT414","article-title":"A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt\u2019s lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J Med Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3390\/cancers15082285","article-title":"Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts","volume":"15","author":"Kurz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821671-2.00040\u20134","article-title":"Non-hodgkin lymphoma","author":"Huang","year":"2023","journal-title":"Lanzkowsky\u2019s Manual Pediatr Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","article-title":"Malignant lymphoma 1. The histology and staging of 473 patients at the national cancer institute. Report","volume":"50","author":"Anderson","year":"1982","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02966\u20138","article-title":"Curative radiotherapy for primary orbital lymphoma","volume":"54","author":"Bhatia","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860701)58:1<100::AID-CNCR2820580118>3.0.CO;2-1","article-title":"Malignant lymphomas of the thyroid gland analysis of 79 patients with emphasis on histologic prognostic factors","volume":"58","author":"Aozasa","year":"1986","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.2.216","article-title":"Malignant lymphoma: cardiac involvement at initial presentation","volume":"5","author":"Gill","year":"1987","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19860801)58:3<699::AID-CNCR2820580317>3.0.CO;2-E","volume-title":"Lymphomas of salivary glands","author":"Gleeson","year":"1986"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19890215)63:4<799::AID-CNCR2820630432>3.0.CO;2-5","volume-title":"Primary adrenal lymphoma","author":"Harris","year":"1989"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90308\u20136","article-title":"Malignant lymphoma of the testis","volume":"81","author":"Doll","year":"1986","journal-title":"Am J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851215)56:12<2932::AID-CNCR2820561234>3.0.CO;2-H","article-title":"Malignant lymphomas involving the prostate A study of 13 cases","volume":"56","author":"Bostwick","year":"1985","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5761\/ATCS.CR.10.01651","article-title":"A case of diffuse large B-cell lymphoma of the lung demonstrating diffuse ground-glass shadows","volume":"17","author":"Ogata-Suetsugu","year":"2011","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.JASC.2015.02.002","article-title":"Cytologic findings of hematologic Malignancies in bronchoalveolar lavage fluid","author":"Murro","year":"2015","journal-title":"J Am Soc Cytopathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1513\/ANNALSATS.201503-165OC","article-title":"Endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis and subtyping of lymphoma","volume":"12","author":"Grosu","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.MIBIO.2004.08.004","article-title":"Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography\/computed tomography hardware fusion for staging of patients with lymphoma","volume":"6","author":"Allen-Auerbach","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1148\/RADIOL.2323030985","article-title":"Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT","volume":"232","author":"Schaefer","year":"2004","journal-title":"Radiology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2007-07\u2013101899","article-title":"Imaging in staging of Malignant lymphoma: a systematic review","volume":"111","author":"Kwee","year":"2008","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-003-1375-Y","article-title":"FDG-PET\/CT in re-staging of patients with lymphoma","volume":"31","author":"Freudenberg","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11547-008-0348\u20134","article-title":"Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study","volume":"114","author":"Stecco","year":"2009","journal-title":"Radiol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0B013E3181AFBB36","article-title":"Whole-body MRI, including diffusion-weighted imaging, for the initial staging of Malignant lymphoma: comparison to computed tomography","volume":"44","author":"Kwee","year":"2009","journal-title":"Invest Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/OR.9.1.85","article-title":"Echocardiographic and pathological characteristics of cardiac metastasis in patients with lymphoma","volume":"9","author":"Meng","year":"2002","journal-title":"Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.12998\/WJCC.V7.I2.191","article-title":"Cardiac involvement in disseminated diffuse large B-cell lymphoma, successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature","volume":"7","author":"Al-Mehisen","year":"2019","journal-title":"World J Clin Cases"},{"key":"B31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/S11936-018-0625-Z","article-title":"Evaluation and management of cardiac tumors","volume":"20","author":"Palaskas","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1-20","DOI":"10.1007\/S12574-020-00502\u20139","article-title":"Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction","volume":"19","author":"Onishi","year":"2021","journal-title":"J Echocardiogr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/EHJCI\/JEAA341","article-title":"Echocardiographic evaluation of patients undergoing cancer therapy","volume":"22","author":"Frey","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30535\u20131","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJCARD.2013.08.033","article-title":"Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study","volume":"168","author":"Jurczak","year":"2013","journal-title":"Int J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/HON.13_2880","article-title":"CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH-GRADE B-CELL LYMPHOMA, NOS \u2013 AN LLMPP PROJECT","volume":"39","author":"Collinge","year":"2021","journal-title":"Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12\u2013820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-14\u2013153","article-title":"Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis","volume":"14","author":"He","year":"2014","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2014-06\u2013538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30177\u20137","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70020","article-title":"Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS","volume":"207","author":"Hossain","year":"2025","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016226","article-title":"CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366\u20130","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.14282","article-title":"Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable","volume":"175","author":"Landsburg","year":"2016","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/EJH.13219","article-title":"Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome","volume":"102","author":"Pedersen","year":"2019","journal-title":"Eur J Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.12343","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases","volume":"162","author":"Perry","year":"2013","journal-title":"Br J Haematol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical significance of MYC expression and\/or \u201chigh-grade\u201d morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S12185-016-1989-Z","article-title":"Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"103","author":"Miyamoto","year":"2016","journal-title":"Int J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S243753","article-title":"High-grade B-cell lymphomas, not otherwise specified: A study of 41 cases","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1781511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:33Z","timestamp":1773812133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1781511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":58,"alternative-id":["10.3389\/fonc.2026.1781511"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1781511","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1781511"}}